SeqLL Announces Cash and Stock Dividend Record Date
16 9월 2023 - 6:24AM
SeqLL Inc. (“SeqLL” or the “Company”) (Nasdaq: SQL, SQLLW),
announced today that its board of directors has set September 26,
2023 as the record date for its special stock dividend and cash
dividend to be made to the holders of its common stock pursuant to
the terms of the Agreement and Plan of Reorganization dated as of
May 29, 2023, as amended (the “Merger Agreement”), by and among the
Company, SeqLL Merger LLC, Atlantic Acquisition Corp., Atlantic
Merger LLC, Lyneer Investments, LLC, IDC Technologies, Inc. and
Lyneer Management Holdings LLC. The dividend distribution of shares
of common stock of the Company and the cash dividend will be made
to all SeqLL common stockholders of record as of the close of
business on September 26, 2023 (the "Record Date"). The cash and
stock dividends, which are contingent upon, and subject to, the
consummation of the transactions contemplated by the Merger
Agreement, are expected to be completed on or about October 2, 2023
(the "distribution date"), subject to certain conditions.
The amount of the cash dividend will be
determined in connection with the closing of the transactions
contemplated by the Merger Agreement. The number of shares to be
issued in the stock dividend will be determined based on the price
per share at which the Company’s common stock is sold in a public
offering to be completed prior to the closing under the Merger
Agreement. No fractional shares will be distributed in the stock
dividend. Additional information regarding the cash dividend and
the stock dividend is set forth under the heading “Proposal I – The
Merger Proposal” in the Company’s proxy statement included in the
Company’s Schedule 14A filed with the Securities and Exchange
Commission on August 10, 2023 (the “Proxy Statement”).
No vote or action is required by SeqLL
shareholders to receive the special stock and cash dividends. SeqLL
shareholders who hold their shares through brokers or other
nominees will have their shares of common stock and cash dividend
credited to their accounts by their nominees or brokers.
Shareholders are encouraged to consult with
their financial advisor regarding the specific implications of
trading SeqLL common stock prior to or on the Record Date.
About SeqLL Inc.
SeqLL is a technology company providing life
sciences instrumentation and research services in collaborative
partnerships aimed at the development of novel scientific assets
and intellectual property across multiple “omics” fields. The
Company leverages its expertise with the True Single Molecule
Sequencing (“tSMS®”) platform to empower scientists and researchers
with improved genetic tools to better understand the molecular
mechanisms of disease that is essential to the continued
development of new breakthroughs in genomic medicine, and that
hopefully address the critical concerns involved with today’s
precision medicine.
Forward Looking Statements
This press release contains certain
forward-looking statements. Forward-looking statements are based on
the Company's current expectations and assumptions. The Private
Securities Litigation Reform Act of 1995 provides a safe-harbor for
forward-looking statements. These statements may be identified by
the use of forward-looking expressions, including, but not limited
to, “expect,” “anticipate,” “intend,” “plan,” “believe,”
“estimate,” “potential,” “predict,” “project,” “should,” “would”
and similar expressions and the negatives of those terms.
Forward-looking statements include statements made about the
proposed special stock and cash dividends and the proposed
transactions contemplated by the Merger Agreement, including the
proposed public offering of the Company’s common stock, the net
proceeds of which will be used to, among other things, effect the
transactions contemplated by the Merger Agreement. Prospective
investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this
presentation. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events or otherwise. Important factors that
could cause actual results to differ materially from those in the
forward-looking statements are set forth in the Company’s filings
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the year ended December 31, 2022 under the
caption “Risk Factors.”
This Press Release does not constitute an offer
of any securities for sale under the Capital Raise. The securities
to be issued in the Merger will not be registered under the
Securities Act of 1933, as amended, and may not be offered or sold
in the United States absent registration or an applicable exemption
from registration requirements. SeqLL stockholders should read the
Proxy Statement for additional information regarding the proposed
special stock dividend and cash dividend. SeqLL stockholders can
review the Proxy Statement and the Merger Agreement and any other
relevant documents for free at the SEC’s website, www.sec.gov.
Contacts:
John W. Kennedy
Investor Relations
Tel: +1 (914) 727-7764
Email: jwkennedy@seqll.com
SeqLL (NASDAQ:SQL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
SeqLL (NASDAQ:SQL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024